Floatz logo

G 207

Supratentorial Neoplasms, Malignant

Gregory K. Friedman, MDgene_therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Supratentorial Neoplasms, Malignant cohort.

Asset / SponsorPhaseRating
Lonafarnib
M.D. Anderson Cancer Center
Phase 1CC
Voluven
National Taiwan University Hospital
N/ANR

Same molecule, other indications

G 207 is also rated in:

malignant gliomaDormant
CCC
Indicative ·
48 / 100
View asset →
primitive neuroectodermal tumorDormant
CC
Indicative ·
47 / 100
View asset →
cerebral primitive neuroectodermal tumorDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →